Sep 13, 2023 / 01:30PM GMT
Unidentified Analyst -
Amazing. Thank you, everyone. You've got Patrick on the U.S. Medtech team. I'm obviously delighted today to have Jose Almeida, the CEO of Baxter; and Clare Trachtman, who runs the IR function to join us for what should be a fun chat. Before I get started, we've got the delightful disclosures, Morganfamily.com/researchdisclosures and then also you can reach out to your sales rep if any of you feel -- on and need to do so.
Questions and Answers:
Unidentified Analyst -Thank you so much for joining us both and Joe, maybe if we could start with sort of a bigger picture question for Baxter. Innovation and driving growth up to that mid-single-digit range is kind of a key focus. How do you feel the pipeline of innovation is looking and what are you most excited about?
Jose E. Almeida - Baxter International Inc. - Chairman of the Board, President & CEO
I think we look at the growth story for Baxter in 3 different vectors. The first vector is acceleration of commercial execution. So going to areas of health